Search

Sharad B Murdande

from East Lyme, CT
Age ~62
Get Report
Also known as:
Murdande Sharad, Sharad E
Related to:
Sanjana S Murdande, 28
Connected to:
Cathy G Murdaugh, 65Connie J Murdaugh, 54Daniel K Murdaugh, 59Doyle Murdaugh, 81Jack C Murdaugh, 81Joe J Murdaugh, 88Latrell Murdaugh, 48Marshall T Murdaugh, 65Megan D Murdaugh, 30Ruby A Murdaugh, 74

Sharad Murdande Phones & Addresses

  • East Lyme, CT
  • 42 Yorkshire Dr, Waterford, CT 06385 (860) 447-2449
  • Groton, CT
  • San Diego, CA
  • Corvallis, OR

Work

Company: Pfizer Position: Principal scientist

Skills

Extemporaneous Preparation • Formulation Development • In Vivo • Pharmaceutical Research • Gmp • Nanotechnology • Drug Metabolism • Regulatory Affairs • Nanoparticles • Lipid Drug Delivery • Dissolution • Drug Discovery • Drug Delivery • Pharmaceutics • Drug Development • Clinical Development • Regulatory Submissions • Cmc • Formulation • Project Management • Pharmaceutical Industry • Fda • Solubilization • Ind • Pharmacokinetics • Spray • Biopharmaceuticals

Industries

Pharmaceuticals

Professional Records

License Records

Sharad Balasaheb Murdande

Address:
Groton, CT
Phone:
(860) 715-5975 (Work)
(860) 715-4473 (Fax)
License #:
RPH04264 - Active
Category:
Pharmacy
Issued Date:
Sep 4, 2001
Expiration Date:
Jun 30, 2017
Type:
Pharmacist

Resumes

Resumes

Sharad Murdande Photo 1

Sharad Murdande

View page
Location:
Waterford, CT
Industry:
Pharmaceuticals
Work:
Pfizer
Principal Scientist
Skills:
Extemporaneous Preparation
Formulation Development
In Vivo
Pharmaceutical Research
Gmp
Nanotechnology
Drug Metabolism
Regulatory Affairs
Nanoparticles
Lipid Drug Delivery
Dissolution
Drug Discovery
Drug Delivery
Pharmaceutics
Drug Development
Clinical Development
Regulatory Submissions
Cmc
Formulation
Project Management
Pharmaceutical Industry
Fda
Solubilization
Ind
Pharmacokinetics
Spray
Biopharmaceuticals

Publications

Us Patents

Epidural Administration Of Therapeutic Compounds With Sustained Rate Of Release

View page
US Patent:
6428529, Aug 6, 2002
Filed:
Sep 16, 1997
Appl. No.:
08/931867
Inventors:
Andres Gruber - San Diego CA
Sharad B. Murdande - San Diego CA
Taehee Kim - San Diego CA
Sinil Kim - Solana Beach CA
Assignee:
SkyePharma Inc. - San Diego CA
International Classification:
A61M 3100
US Classification:
604512, 604500, 424450, 424457
Abstract:
A drug delivery system provides sustained-release delivery of therapeutic biologically active compounds administered epidurally. In the preferred embodiment the biologically active compound is an opioid, which is encapsulated within the non-concentric internal aqueous chambers or bilayers of multivesicular liposomes. The opioid is released over an extended period of time when the liposomes are introduced epidurally as a single dose for sustained analgesia.

Self-Emulsifying Formulations Of Cholesteryl Ester Transfer Protein Inhibitors

View page
US Patent:
6962931, Nov 8, 2005
Filed:
Jun 19, 2002
Appl. No.:
10/175643
Inventors:
Michael J. Gumkowski - Old Lyme CT, US
Lombardo Franco - Gales Ferry CT, US
Sharad B. Murdande - Waterford CT, US
Michael E. Perlman - Old Saybrook CT, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61K031/47
A61K031/35
A61K031/335
US Classification:
514313, 514312, 514314, 514455, 514452, 514451
Abstract:
CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise.

Sustained-Release Liposomal Anesthetic Compositions

View page
US Patent:
8182835, May 22, 2012
Filed:
Apr 1, 2005
Appl. No.:
11/097756
Inventors:
Sinil Kim - Solana Beach CA, US
Taehee Kim - Los Angeles CA, US
Sharad Murdande - Groton CT, US
Assignee:
Pacira Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 9/127
US Classification:
424450, 364 41, 364 43, 364 46
Abstract:
The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

Self-Emulsifying Formulations Of Cholesteryl Ester Transfer Protein Inhibitors

View page
US Patent:
20060014788, Jan 19, 2006
Filed:
Sep 8, 2005
Appl. No.:
11/222908
Inventors:
Michael Gumkowski - Old Lyme CT, US
Franco Lombardo - Gales Ferry CT, US
Sharad Murdande - Waterford CT, US
Michael Perlman - Old Saybrook CT, US
International Classification:
A61K 31/4706
US Classification:
514313000
Abstract:
CETP Inhibitors have improved solubility and bioavailability in a lipophilic vehicle comprising a digestible oil, a lipophilic solvent, or a surfactant. Preferred such compositions are self-emulsifying or self-microemulsifying, and comprise 1. a CETP inhibitor; 2. a cosolvent; 3. a surfactant having an HLB of 1 to 8; 4. a surfactant having an HLB of over 8 to 20; and 5. optionally, a digestible oil.

Sustained-Release Liposomal Anesthetic Compositions

View page
US Patent:
20120231070, Sep 13, 2012
Filed:
May 21, 2012
Appl. No.:
13/476823
Inventors:
Sinil Kim - La Jolla CA, US
Taehee Kim - Carlsbad CA, US
Sharad Murdande - Waterford CT, US
Assignee:
PACIRA PHARMACEUTICAL, INC. - San Diego CA
International Classification:
A61K 9/127
A61K 31/40
A61K 31/165
A61K 31/445
US Classification:
424450, 514315, 514426, 514619
Abstract:
The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multi vesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

Sustained-Release Liposomal Anesthetic Compositions

View page
US Patent:
20130189349, Jul 25, 2013
Filed:
Mar 6, 2013
Appl. No.:
13/787690
Inventors:
Taehee Kim - Carlsbad CA, US
Sharad Murdande - Waterford CT, US
Assignee:
Pacira Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 47/02
A61K 47/12
A61K 9/00
US Classification:
424450, 514330, 264 41
Abstract:
The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multi vesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

Sustained-Release Liposomal Anesthetic Compositions

View page
US Patent:
20130344132, Dec 26, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/842198
Inventors:
Taehee Kim - Carlsbad CA, US
Sharad Murdande - Waterford CT, US
Assignee:
PACIRA PHARMACEUTICALS, INC. - San Diego CA
International Classification:
A61K 9/127
A61K 31/445
US Classification:
424450, 514330, 546245
Abstract:
The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multi vesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

Epidural Administration Of Therapeutic Compounds With Sustained Rate Of Release

View page
US Patent:
59318090, Aug 3, 1999
Filed:
Jul 14, 1995
Appl. No.:
8/502569
Inventors:
Andres Gruber - San Diego CA
Sharad B. Murdande - San Diego CA
Taehee Kim - San Diego CA
Sinil Kim - Solana Beach CA
Assignee:
Depotech Corporation - San Diego CA
International Classification:
A61M 3100
US Classification:
604 49
Abstract:
A drug delivery system provides sustained-release delivery of therapeutic biologically active compounds administered epidurally. In the preferred embodiment the biologically active compound is an opioid, which is encapsulated within the non-concentric internal aqueous chambers or bilayers of multivesicular liposomes. The opioid is released over an extended period of time when the liposomes are introduced epidurally as a single dose for sustained analgesia.
Control profile
Sharad B Murdande from East Lyme, CT, age ~62 Get Report